A Case Report: Internal Carotid Artery Dissection Presenting as Hoarseness Secondary to Vocal Cord Palsy - European Medical Journal
×

Browse

A Case Report: Internal Carotid Artery Dissection Presenting as Hoarseness Secondary to Vocal Cord Palsy

| Download as | PDF
8 Mins
EMJ Neurology 9.1 2021 Feature Image
Authors:
*Foon Ng Kee Kwong,1 Fiona Brodie,2 Claire McArthur,3 Fiona MacGregor4
Disclosure:

The authors have declared no conflicts of interest.

Acknowledgements:

Dr Trovato and Dr Tognetti contributed equally.

Received:
09.08.20
Accepted:
27.10.20
Citation
EMJ. ;9[1]:66-71. DOI/10.33590/emjneurol/20-00208. https://doi.org/10.33590/emjneurol/20-00208.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Abstract

Internal carotid artery (ICA) dissection is a rare cause of a cranial nerve X palsy. Patients more commonly present with stroke or transient ischaemic attacks. An undetected and untreated ICA dissection can have serious consequences. Here, the authors present two cases of ICA dissection presenting with isolated vagal nerve palsy presenting with hoarseness. CT scans provided good evidence of ICA in both cases. The patients were treated with antiplatelet agents and made a good recovery with complete resolution of symptoms.

INTRODUCTION

Vocal cord paralysis or weakness can be a symptom of malignancy, caused by viral infection, iatrogenic, a result of trauma, idiopathic, or a result of brainstem infarction, in particular lateral medullary syndrome.1 Internal carotid artery (ICA) dissection is a rare cause of an X cranial nerve palsy. This particular nerve palsy is present in only 16% of ICA dissection cases.2 Isolated cranial nerve palsies are an unusual presentation of ICA dissection. Patients more commonly present with stroke or transient ischaemic attacks. They can also present with multiple lower cranial nerve palsies and other concurrent neurological deficits, such as Horner’s syndrome, due to compression of sympathetic nerves around the ICA by a thrombus.2 An undetected and untreated ICA dissection can have serious consequences.3 Here, the authors present two cases of ICA dissection with isolated vagal nerve palsy.

CASE 1

Presentation

A previously healthy male, who occasionally smoked, presented at the age of 42 with a sudden onset of hoarseness and swallowing difficulties, but with no history of trauma. They also reported pain over the right side of their head and face. They were initially treated in primary care with antibiotics, but there was no improvement. A contrast-enhanced CT scan of their chest and abdomen did not reveal the cause of their symptoms. They were then referred to the otolaryngology service where a right vocal cord palsy was found on fibreoptic laryngoscopy. Due to some concern about the appearance of the right piriform fossa, they underwent examination under general anaesthetic, but this was unremarkable.

Investigation

A further CT scan was requested in order to investigate a potential cause of the vocal cord palsy in the head and neck. The standard protocol for contrast CT of the neck alone for otorhinolaryngological (ear, nose, and throat) pathology in the authors’ local department was utilised. This is a split bolus technique: 45 mL of Omipaque™ (GE Healthcare, Chicago, Illinois, USA; iohexol) 300 administered at a rate of 1.5 mL/sec, with a further 45 mL bolus at the same rate with an inter-bolus delay of 30 secs. This resulted in neck images being acquired with good soft tissue and vascular contrast at 90 secs following the start of the first contrast injection. Axial coverage was from above the frontal sinuses to the clavicles. This CT scan demonstrated a thickening of the right ICA at the skull base with narrowing of the vessel lumen and eccentric hypodensity, strongly suggestive of arterial dissection (Figure 1). An MRI was also performed using axial fat-saturated sequences and this revealed corresponding eccentric T2 iso- or hyperintensity around the right ICA true lumen, confirming the suspicion of dissection (Figure 2).

Figure 1: Axial CT image depicting the intramural haematoma.

Figure 2: Axial MRI image of the intramural haematoma.

Treatment and Outcome

Antiplatelet therapy was commenced for a period of 6 months. Over the next 6 months, their vocal cord palsy persisted but their left vocal cord was compensating very well, allowing them to produce a stable and strong voice. They were referred to the speech and language therapy team, and a year after their first presentation their right vocal cord had fully recovered.

CASE 2

Presentation

A 29-year-old female patient, previously healthy, presented with a sudden onset of difficulty swallowing. Shortly after the onset of their dysphagia, they developed hoarseness. Although their physical activities were not affected, they found themselves more breathless walking up the stairs and found it difficult to complete sentences. They also noticed a left-sided pulsatile tinnitus when lying on their left side. They attended their general practitioner and were treated with two courses of antibiotics. They reported no history of trauma. Onward referral was made to the otolaryngology service. Further investigation was arranged due to the unresolved cause of the issue. Fibreoptic examination revealed impaired left vocal cord movement.

Investigation

A CT scan was organised, and the split-bolus contrast CT showed narrowing of the lumen of the left ICA and eccentric mural thickening, consistent with a left ICA dissection (Figure 3). The same split-bolus sequence was used. A 75 mL bolus was administered at 2.5 mL/sec and the thorax was scanned at 65 secs delay with arms up. This was quickly followed by a 50 mL bolus at 2.0 mL/sec and the neck was scanned with arms down at 25 secs delay. The result was a split-bolus neck scan at approximately 100 secs following the start of the first injection.

Figure 3: Axial CT image depicting the intramural haematoma.

Treatment and Outcome

Following the diagnosis, the individual was referred to the stroke team and began antiplatelet therapy for a duration of 6 months to reduce the risk of thromboembolism.4 Follow-up CT angiogram revealed a near-complete resolution. When reviewed a few months later, the patient reported that their swallowing and voice symptoms had completely resolved. The only residual symptom was the awareness of intermittent pulsatile tinnitus in their left ear at night. Genetic testing was carried out and no underlying genetic connective tissue disorder was discovered.

DISCUSSION

ICA dissection can be either intracranial or extracranial. Although rare with an incidence between 2.6 and 2.9 per 100,000, extracranial ICA dissection is still more common than intracranial ICA in the adult European population.5 It is also more common in males, usually aged 50–59.6

It presents with stroke in 67% of cases and Horner’s syndrome in 28–58% of cases.7 Other symptoms include ipsilateral neck, facial or eye pain, ptosis, and visual disturbance.1,3,8 Approximately 3–16% of patients with ICA dissection present with lower cranial nerve palsies. The most affected cranial nerves are X, XI, and XII.3,8,9 As they exit the skull base through the jugular foramen and hypoglossal canal, these nerves travel in the carotid sheath and are therefore in close relation to the ICA, especially cranial nerves X and XII, which travel a longer distance along its length. In the neck, the vagus nerve can be found on both sides, and enters the carotid sheath and travels inferiorly between the common carotid artery and the internal jugular vein all the way to the base of the neck. The left vagus nerve then branches and gives rise to the left recurrent laryngeal nerve, which loops around the aortic arch, while the right vagus nerve branches at the level of the right subclavian artery to loop around it. The recurrent laryngeal nerves travel back up to provide motor innervations to the vocal cords. The vagus nerve also contributes to the oesophageal plexus by sending parasympathetic and afferent fibres. Mass effect from an ICA haematoma on the vagus nerve can give rise to hoarseness or dysphagia or both. It is interesting to note that ICA dissections that exhibit lower cranial nerve paralysis are less often associated with cerebral ischaemia.3 The cervical plexus lies deep to the carotid sheath. It provides sensory innervations to the ear, scalp, neck, and upper part of the chest. Compression of these nerves could account for the head and face pain experienced by the first patient.10 ICA is usually unilateral but can be bilateral in up to 10% of patients.9 Compared to unilateral disease, bilateral disease causes a greater obstruction of cerebral blood flow and is more likely to lead to cerebral ischaemia. A concurrent vertebral artery dissection can also be found in more than one-fifth of cases.11

ICA dissection can occur spontaneously or can be attributed to trauma in 40% of cases.1,3,12 The mechanism of injury is usually blunt force trauma, such as a direct blow to the neck or sudden neck movements.13 Other risk factors for ICA dissection include systemic conditions and congenital tissue defects: fibromuscular dysplasia, Marfan’s syndrome, Ehlers–Danlos syndrome, α-1 antitrypsin deficiency, Behçet’s syndrome, and osteogenesis imperfecta Type 1.1,3,12 The disease is caused by a tear in the wall of the vessel creating a false lumen and the formation of a mural haematoma, thereby compressing and narrowing the true lumen.3 Formation of a haematoma leads to mass effect on the surrounding structures, and in the case of a cervical ICA dissection, it impacts on the other structures within the carotid sheath.14

It has been suggested in the literature that ICA dissection should be diagnosed through duplex ultrasonography or MRI.3,14 A further CT angiogram can then help localise and evaluate the extent of the ICA dissection.2,14 In the case of a haematoma, MRI scans show hyperintensity on T1 and T2 images or a delineation around the blood clot.2 One of the limitations of duplex ultrasonography is that unless there is a change in the blood flow caused by the dissection, the diagnosis can be missed.15 In the authors’ local practice, patients presenting with a vocal cord palsy are initially referred for a CT scan encompassing the skull base to the diaphragm. In both cases, contrast CT scans using split-bolus CT provided good evidence of ICA dissection. MRI was used in one case to confirm the diagnosis. This was supported by the findings of one study that showed that the evaluation accuracy of CT and MRI are comparable in the diagnosis of carotid and vertebral artery dissection.16

The prognosis of ICA dissection is generally good and there is full or almost full recovery of symptoms in up to 80% of cases.7 Although it can resolve spontaneously in a large number of patients, ICA dissection is usually managed with antithrombotics to reduce the risk of stroke, usually antiplatelets or warfarin;1,6,17 however, there is no compelling evidence to favour one over the other.18 Although it is does not treat the dissection itself, the antithrombotic therapy leads to a higher rate of recanalisation within the first 2–3 months.19 With the right management, the outcome of an ICA dissection is good.1

CONCLUSION

After excluding malignancy in a patient with vocal cord palsy, particularly in a sudden onset or if associated with facial or neck pain or headache, physicians should consider ICA dissection as another potential cause. Although rare, ICA dissection can lead to serious complications, such as embolic stroke, transient ischaemic attack, or aneurysms.2,20,21 MRI scans have been suggested as the radiological investigation of choice, however, in both cases, split-bolus CT has shown to provide good evidence of ICA dissection. Prompt and appropriate treatment should be started using antithrombotics and, in most cases, this will lead to a good outcome.

References
Lechner M et al. Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy. 2011;3(11):1317-40. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342(6165):1432-3. Hegasy Illustartions. Cancer Therapy by Inhibition of Negative Immune Regulation (CTLA4, PD1). Available at: https://www.hegasy.de/dwnlds/11_Hegasy_CTLA4_PD1_Immunotherapy.pdf. Last accessed: 02 April 2020. Postow M et al. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974-82. Barkholt L, Bregni M. Current immunotherapy for solid tumors. Immunotherapy. 2009;1(3):483-93. de La Cruz-Merino L et al. Breast cancer immunology and immunotherapy: current status and future perspectives. Int Rev Cell Mol Biol. 2017;331:1-53. Disis M. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother. 2011;60(3):433-42. Melero I et al. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 2014;4(5):522-6. Galon J et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol. 2014;232(2):199-209. Mlecnik B et al. Integrative analyses of colorectal cancer show Immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44(3):698-711. Anitei MG et al. Prognostic and predictive values of the Immunoscore in patients with rectal cancer. Clin Cancer Res. 2014;20(7):1891-9. Mlecnik B et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 2016;8(327):327ra26. Pagès F et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128-39. Hermitte F. Biomarkers immune monitoring technology primer: Immunoscore® Colon. J Immunother Cancer. 2016;4:57. Jiang Y et al. ImmunoScore signature: a prognostic and predictive tool in gastric cancer. Ann Surg. 2018;267(3):504-13. Ogino S, Giannakis M. Immunoscore for (colorectal) cancer precision medicine. Lancet. 2018;391(10135):2084-6. Wargo J et al. Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol. 2016;41:23-31. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197-218. Peng D et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527(7577):249-53. Riley R et al. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18(3):175-196. Esteva F et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019:20(3):e175-86. Gujar S et al. Heating it up: oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies. OncoImmunology. 2018;7(8):e1442169. Ciardiello D et al. Immunotherapy of colorectal cancer: challenges for therapeutic efficacy. Cancer Treat Rev. 2019;76:22-32. Sevenich L. Turning ‘cold’ into ‘hot’ tumors – opportunities and challenges for radio-immunotherapy against primary and metastatic brain cancers. Front Oncol. 2019;9:163. Menon S et al. Advances in cancer immunotherapy in solid tumors. Cancers. 206;8(12):106. Woo SR et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41(5):830-42. Novartis Pharmaceuticals. Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas. NCT03172936. https://clinicaltrials.gov/ct2/show/NCT03172936. Aduro Biotech, Inc. Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas. NCT02675439. https://clinicaltrials.gov/ct2/show/NCT02675439. Aduro Biotech, Inc. Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer. NCT03937141. https://clinicaltrials.gov/ct2/show/NCT03937141. Feng X et al. Bioactive modulators targeting STING adaptor in cGAS-STING pathway. Drug Discov Today. 2020;25(1):230-7. Helleday T. Making immunotherapy ‘cold’ tumours ‘hot’ by chemotherapy-induced mutations — a misconception. Ann Oncol. 2019;30(3):360-1. Sharma P et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707-23. Waldmann T, Morris J. Development of antibodies and chimeric molecules for cancer immunotherapy. Adv Immunol. 2006;90:83-131. Zitvogel L et al. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8(3):151-60. Buch S, Chatra L. Immunotherapy and its advances in the management of head-and-neck cancer. CHRISMED J Health Res. 2019;6(4):199-203. Hanson H et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity. 2000;13(2):265-76. Chiappinelli K et al. Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 2016;76(7):1683-9. Yau H et al. The cancer epigenome: exploiting its vulnerabilities for immunotherapy. Trends Cell Biol. 2019;29(1):31-43. Royal Marsden NHS Foundation Trust. Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE) (EMERGE). NCT03812796. https://clinicaltrials.gov/ct2/show/NCT03812796. Cartwright E et al. EMERGE: Epigenetic modulation of the immune response in gastrointestinal cancers. Ann Oncol. 2019;30(5):v251-2. Zheng Y et al. Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer. Cell Immunol. 2015;294(1):54-9. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine. NCT01088789. https://clinicaltrials.gov/ct2/show/NCT01088789. University of Wisconsin, Madison. Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition. NCT03275597. https://clinicaltrials.gov/ct2/show/NCT03275597. Vacchelli E et al. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2012;1(2):179-88. Song A, Lu B. Utility of stereotactic ablative radiotherapy/stereotactic body radiation therapy in the setting of oligometastatic non-small cell lung cancer. J Thorac Dis. 2018;10(2):657-60. Nicodemus C. Antibody-based immunotherapy of solid cancers: progress and possibilities. Immunotherapy. 2015;7(8):923-39. Haanen J. Converting cold into hot tumors by combining immunotherapies. Cell. 2017;170(6):1055-6. Ribas A et al. Oncolytic virotherapy promotes intratumoural T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109-19.e10 Giraudo L et al. Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives. Immunotherapy. 2015;7(9):999-1010. Achard C et al. Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. EBioMedicine. 2018;31:17-24. Oldford S, Marshall J. Mast cells as targets for immunotherapy of solid tumors. Mol Immunol. 2015;63(1):113-24. Bofill-De Ros X. Oncolytic adenovirus controlled by microRNA response element. Available at: https://commons.wikimedia.org/wiki/File:Oncolytic_adenovirus_controlled_by_microRNA_response_element.png. Last accessed: 02 April 2020. Twumasi-Boateng K et al. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer. 2018;18(7):419-32. Amgen. Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) (MASTERKEY232). NCT02626000. https://clinicaltrials.gov/ct2/show/NCT02626000. National Cancer Institute (NCI). Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma. NCT02965716. https://clinicaltrials.gov/ct2/show/NCT02965716. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer. NCT01696877. https://clinicaltrials.gov/ct2/show/NCT01696877. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas. NCT03153410. https://clinicaltrials.gov/ct2/show/NCT03153410. Pandey V, Storz P. Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma. Expert Rev Anticancer Ther. 2019;19(6):473-82. Antonarakis E et al. Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP). J Clin Oncol. 2017;35(Suppl):5077. Schmidt C. The benefits of immunotherapy combinations. Nature. 2017;552(7685):S67-9. Srivatsan S et al. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccin Immunother. 2014;10(1):52-63. Lundqvist A, Childs R. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions. J Immunother. 2005;28(4):281-8. Klebanoff C et al. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med. 2016;22(1):26-36. Kosti P et al. Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors. Front Immunol. 2018;9:1104. Jang JY et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg. 2005;241(1):77-84. Simmonds P et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94(7):982-99. Brooks E et al. Stereotactic ablative radiation therapy combined with immunotherapy for solid tumors. Cancer J. 2016;22(4):257-66. Heaton K, Grimm E. Cytokine combinations in immunotherapy for solid tumors: a review. Cancer Immunol Immunother. 1993;37(4):213-9. Bartholeyns J et al. Adoptive immunotherapy of solid tumors with activated macrophages: experimental and clinical results. Anticancer Res. 1991;11(3):1201-4. Puts M et al. Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review. Ann Oncol. 2014;25(3):564-77. Fessas P et al. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology. 2020;159(2):167-77. Young A et al. The balancing act between cancer immunity and autoimmunity in response to immunotherapy. Cancer Immunol Res. 2018;6(12):1445-52. Vaishnav R et al. Unforeseen consequences of cancer immunotherapy. Int J Nanomed. 2018;3(1). doi: 10.18203/issn.2456-3994. Osipov A et al. From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. Adv Cancer Res. 2019;143:63-144. Andersen M. Anti-cancer immunotherapy: breakthroughs and future strategies. Semin Immunopathol. 2019;41(1):1-3. Van Tellingen O et al. Overcoming the blood–brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015;19:1-12. Mocellin S et al. Adjuvant immunotherapy for solid tumors: from promise to clinical application. Cancer Immunol Immunother. 2002;51(11-12):583-95. Mahoney K et al. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561-584. Pham T et al. An update on immunotherapy for solid tumors: a review. Ann Surg Oncol. 2018;25(11):3404-12.